![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/07/03/2908117/0/en/IntelGenx-Obtains-Preliminary-Efficacy-Results-for-the-BUENA-Montelukast-VersaFilm-Phase-2a-Clinical-Trial-in-Patients-with-Mild-to-Moderate-Alzheimer-s-Disease.html
https://www.globenewswire.com/news-release/2024/06/11/2896825/0/en/IntelGenx-Announces-Initiation-of-the-Sale-and-Investment-Solicitation-Process.html
https://www.globenewswire.com/news-release/2024/05/28/2889137/0/en/IntelGenx-Obtains-Court-Approval-of-a-Sale-and-Investment-Solicitation-Process.html
https://www.globenewswire.com/news-release/2024/05/17/2884298/0/en/IntelGenx-Initiates-Restructuring-Proceedings-Under-the-CCAA-to-Implement-a-Review-of-its-Strategic-Alternatives.html
https://www.globenewswire.com/news-release/2024/05/08/2877733/0/en/IntelGenx-Announces-Voting-Results-on-Election-of-Directors.html
https://www.globenewswire.com/news-release/2024/04/08/2859094/0/en/IntelGenx-Announces-First-Parkinson-s-Disease-Patients-Dosed-with-Montelukast-VersaFilm-in-Phase-2-MONTPARK-Clinical-Trial.html
https://www.globenewswire.com/news-release/2024/04/05/2858468/0/en/IntelGenx-Updates-Status-of-Buprenorphine-Buccal-Film-ANDA.html
https://www.globenewswire.com/news-release/2024/03/21/2850139/0/en/IntelGenx-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html
https://www.globenewswire.com//news-release/2024/03/11/2843679/0/en/IntelGenx-Enters-Into-a-Third-Amended-and-Restated-Loan-Agreement-With-atai-Life-Sciences.html
https://www.intelgenx.com/newsrooms/newsrooms1/134-2024-news/980-ntelenxntersntoahirdmendedandestatedoangr20240311